

## ARTICLE

<https://doi.org/10.1038/s41467-020-20520-6>

OPEN

# Dual RNA 3'-end processing of H2A.X messenger RNA maintains DNA damage repair throughout the cell cycle

Esther Griesbach<sup>1</sup>, Margarita Schlackow<sup>1</sup>, William F. Marzluff <sup>2</sup> & Nick J. Proudfoot <sup>1</sup>✉

Phosphorylated H2A.X is a critical chromatin marker of DNA damage repair (DDR) in higher eukaryotes. However, H2A.X gene expression remains relatively uncharacterised. Replication-dependent (RD) histone genes generate poly(A)- mRNA encoding new histones to package DNA during replication. In contrast, replication-independent (RI) histone genes synthesise poly(A)+ mRNA throughout the cell cycle, translated into histone variants that confer specific epigenetic patterns on chromatin. Remarkably *H2AFX*, encoding H2A.X, is a hybrid histone gene, generating both poly(A)+ and poly(A)- mRNA isoforms. Here we report that the selective removal of either mRNA isoform reveals different effects in different cell types. In some cells, RD H2A.X poly(A)- mRNA generates sufficient histone for deposition onto DDR associated chromatin. In contrast, cells making predominantly poly(A)+ mRNA require this isoform for de novo H2A.X synthesis, required for efficient DDR. This highlights the importance of differential H2A.X mRNA 3'-end processing in the maintenance of effective DDR.

<sup>1</sup>Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK. <sup>2</sup>Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA. ✉email: [nicholas.proudfoot@path.ox.ac.uk](mailto:nicholas.proudfoot@path.ox.ac.uk)

**M**etazoans have evolved specific spatial and structural mechanisms to fine-tune the expression of core histone genes with DNA replication. Notably all five canonical histone proteins (H2A, H2B, H3, H4 and the linker histone H1) are expressed from multi-copy gene clusters<sup>1</sup> of replication-dependent (RD) histone genes to ensure their large scale, stoichiometric production in the S-phase of the cell cycle. The molecular basis for this coordinated regulation lies in the assembly of histone locus bodies (HLB)<sup>2,3</sup> over RD histone genes that act to concentrate specific transcription and pre-mRNA processing factors at their sites of action. One such critical HLB component is the histone gene-specific transcription factor NPAT, activated by phosphorylation in late G1 by CyclinE/Cdk2<sup>4–6</sup>. In mammalian cells, transcriptional activation and 3'-end processing combines to cause a 30-fold induction of histone mRNA production during the S-phase<sup>7,8</sup>. As these RD histone genes do not have introns and lack a poly(A) tail, only a single endonucleolytic cleavage reaction is required to generate their mRNA. This RNA 3'-end processing reaction requires two *cis*-elements, a conserved stem-loop (SL) structure followed by a purine-rich region called the histone downstream element (HDE). The SL is bound by the S-phase-specific stem-loop binding protein (SLBP), which is required both for RD histone pre-mRNA 3'-end processing and subsequent mRNA translation and stability<sup>9,10</sup>. The HDE is recognised by base pairing to U7 snRNA as part of a small nuclear ribonucleoprotein (U7 snRNP)<sup>11</sup>. Further 3'-end processing factors are then recruited, including CPSF-73, which catalyses the endonucleolytic cleavage reaction<sup>12</sup>. The full structure of this assembled 3'-end processing complex has been recently established by cryoEM<sup>13</sup>, confirming a remarkable cooperation between histone-specific and a subset of cleavage and polyadenylation (CPA) factors, especially CPSF-73. Once DNA replication is concluded at the end of the S-phase, RD histone mRNA is rapidly degraded by a mechanism involving active translation and SLBP<sup>9</sup>.

Some atypical histone proteins are also required outside of the S-phase, provided by replication-independent (RI) histone genes such as H2A.Z. These encode variant histones that confer a range of epigenetic regulatory processes<sup>14</sup>. RI histone genes are not linked to each other and are distinct from RD histone genes with their pre-mRNA processed by CPA factors like bulk poly(A) mRNA. Under certain circumstances, RD histone genes can also express low levels of polyadenylated mRNA. This often occurs when U7-dependent processing is deficient, leading to RNA polymerase II (Pol II) read-through and subsequent 3'-end processing at a downstream cryptic polyadenylation site (PAS)<sup>15–19</sup>. In addition, it has been shown that some RD histone genes express extended polyadenylated mRNA even under normal physiological conditions, such as upon terminal differentiation<sup>20</sup> or following DNA damage<sup>21</sup>.

The *H2AFX* gene, encoding the H2A variant H2A.X is unique among histone genes in that it employs an intermediate pattern of mRNA 3'-end formation. It expresses both S-phase-specific mRNA ending in the typical SL structure of RD histone mRNA (H2A.X SL mRNA) and RI mRNA ending in a poly(A) tail dictated by a PAS (H2A.X poly(A) mRNA)<sup>22</sup>. Interestingly, *H2AFX* is not located in the histone gene clusters (i.e. outside of HLBs) and has a different promoter structure compared to RD histone genes<sup>23</sup> that enables *H2AFX* transcription also outside S-phase<sup>24</sup>. The H2A.X protein is well-known for its function in the DNA damage response. In mammals it comprises 2–25% of the total chromatin H2A pool<sup>25,26</sup>. Its protein structure is very similar to core H2A apart from a C-terminal extension containing a conserved SQ[E/D]Φ motif. DNA damage leads to the phosphorylation of the serine residue in this motif (Ser139) by PI3K-like kinases including ATM, ATR and DNA-PK, forming


γH2A.X<sup>27–29</sup>. γH2A.X specifically forms on nucleosomes at the damage site and then spreads to wider regions up to megabase lengths of DNA<sup>30,31</sup>. It has been suggested that these γH2A.X chromatin patches act as a platform for the binding of DNA repair factors<sup>32,33</sup>. Even though γH2A.X is dispensable for the initial recognition of DSBs, it is required to maintain the stable association of repair factors at DSB sites<sup>34,35</sup>. This is thought to be critical to tether broken DNA ends together<sup>36</sup>.

We sought to better understand the regulation and molecular consequences of alternative 3'-end formation of *H2AFX* transcripts. While previous work has focused on H2A.X protein, the differential function of its two H2A.X mRNA isoforms in the DNA damage response has not been characterised. Since it has been shown that different human cell lines express different relative ratios of H2A.X mRNA isoforms<sup>24</sup>, we specifically depleted each mRNA isoform in these different cell lines by use of RNA interference (RNAi) or CRISPR-Cas9 gene editing. Our results reveal that when cells express higher levels of H2A.X poly(A) mRNA, such as HeLa and RPE-1, they rely on the *de novo* incorporation of H2A.X into chromatin from this mRNA throughout the whole cell cycle to efficiently signal response to DNA damage by γH2A.X. In contrast, cells that express high levels of the S-phase-specific H2A.X SL mRNA, such as HCT-116 and Jurkat cells, incorporate higher levels of H2A.X into the chromatin during DNA replication. This is sufficient for efficient γH2A.X signalling following DNA damage induction throughout the rest of the cell cycle. It is apparent that the flexible regulation of these two H2A.X mRNA isoforms described in this study is critical to maintain efficient DNA repair processes in different cell types.


## Results

***H2AFX* expresses both poly(A) and SL mRNA isoforms.** We initially catalogued the transcription of histone genes in S- and G1-phase HeLa cells by cell fractionation and RNA-seq analysis (Supplementary Fig. 1a–c). Our goal was to identify RD-histone genes that in addition to the typical SL mRNA also express a cytoplasmic poly(A) mRNA isoform. While most RD histone genes only express SL mRNA in the S-phase (Fig. 1a, Supplementary Fig. 1d and Supplementary Table 1) and RI histone genes generate poly(A) mRNA throughout the cell cycle (Fig. 1b), some RD histone genes express both SL and poly(A) mRNA (Fig. 1c, Supplementary Fig. 1e, f and Table 1). *H2AFX* is the only example of such a “hybrid” histone gene that expresses relatively high levels of poly(A) mRNA compared to S-phase-specific SL mRNA (Fig. 1c). This encodes the variant histone H2A.X associated with the DNA damage response (DDR). The existence of the two H2A.X mRNA isoforms has been previously documented<sup>22</sup>, even though their biological relevance in DDR remains unknown. It is also known that different cell lines express different amounts of H2A.X mRNA isoforms<sup>24</sup>. We therefore elected to study in detail HeLa and RPE-1 cells, that predominantly express H2A.X poly(A) mRNA and compare this to HCT-116 and Jurkat cells that express more H2A.X SL mRNA (Fig. 2a, b). RPE-1 cells are diploid and immortalised, derived from retinal pigment epithelium. Human induced pluripotent stem (iPS) cells, like HeLa cells, express mostly H2A.X poly(A) mRNA (Fig. 2c). To quantitatively distinguish the two H2A.X mRNA isoforms, we used northern blotting with a probe that detects both the SL and poly(A) H2A.X mRNA. Core H4 histone SL mRNA was used as a positive control and methylene blue staining of 18S ribosomal RNA (rRNA) as a loading control. It should be noted that, asynchronous HCT-116 and Jurkat cells have about 10% more S-phase cells compared to HeLa and RPE-1, based on EdU labelling and flow cytometry of each cell type (Fig. 2d, flow cytometry gating strategy shown in Supplementary Fig. 2a).






**Fig. 1 H2AFX expresses poly(A)<sup>+</sup> and poly(A)<sup>-</sup> mRNA.** HeLa cell RNA-seq reads aligned to human genome. Scale indicated in red in upper left corner. pA<sup>-</sup>: rRNA-depleted poly(A)<sup>-</sup> RNA. pA<sup>+</sup>: poly(A)<sup>+</sup> RNA. S and G1: S- and G1-phase-enriched cells. SL: U7-dependent cleavage site. pA: polyadenylation site. Black arrow: direction of Pol II transcription. Maximum read number indicated. Green arrows: poly(A)<sup>-</sup> histone mRNA in G1 fractions derived from 3% S-phase cell contamination (Supplementary Fig. 1b). **a** RNA-seq profile of a typical replication-dependent histone gene. **b** Example of a replication-independent histone gene. **c** H2AFX gene with replication-dependent and independent features.



**Fig. 2 H2AFX expresses both H2A.X poly(A) and SL mRNA isoforms.** **a** H2A.X mRNA northern blot of total RNA from asynchronous HeLa, HCT-116 and RPE-1 cells. H4 SL: core H4 histone SL mRNA. 18S rRNA used as loading control. **b** H2A.X mRNA northern blot of total RNA from asynchronous Jurkat cells. 28S and 18S rRNA used as loading controls. **c** H2A.X mRNA northern blot of total RNA from three different human iPS cell lines. 28S and 18S rRNA used as loading controls. **d** EdU labelling of asynchronous HeLa, HCT-116, RPE-1 and Jurkat cells showing DAPI fluorescent intensity on x-axis and Alexa 647-EdU fluorescent intensity on y-axis.



**Fig. 3 Comparative H2A.X mRNA cell cycle distributions.** **a** Cell cycle synchronisation of HeLa cells by double thymidine block (DTB). Cell cycle profiles (time following DTB release) showing DAPI fluorescent intensity on x-axis and cell count on y-axis (left). H2A.X mRNA northern blot of total RNA (right). Asy: asynchronous cells. Cell cycle phases determined by flow cytometry are indicated. H4 SL: core H4 histone SL mRNA. EEF1A1 mRNA and 18S rRNA used as loading controls. Orange box: S-phase. **b** As in **a** but for HCT-116 cells. **c** Cell cycle profiles of RPE-1 cells synchronised by contact inhibition (time after block release indicated) showing DAPI fluorescent intensity on x-axis and cell count on y-axis (left). H2A.X mRNA northern blot of total RNA from synchronised RPE-1 cells (right). H4 SL: core H4 histone SL mRNA. EEF1A1 mRNA and 18S rRNA used as loading controls.

**Cell cycle profiles of H2A.X SL and poly(A) mRNA isoforms.** To characterise the differential expression patterns of H2A.X mRNA isoforms throughout the cell cycle, HeLa and HCT-116 cells were synchronised by double thymidine block (DTB) at the G1/S-phase border. Following block release, they were collected at the indicated time points and analysed for cell cycle stage (Fig. 3a, b). RPE-1 cells were instead synchronised in G0 by contact inhibition, as described previously<sup>37</sup>, and time points were subsequently collected at 12 hr (G1) and 22 hr (~50% S-phase based on EdU labelling) after cell cycle re-entry (Fig. 3c). Total RNA was extracted from each cell cycle time point and used for northern blotting. Eukaryotic Translation Elongation Factor 1 Alpha 1 (EEF1A1) mRNA was used as an additional loading control. Both HeLa and HCT-116 cells express H2A.X poly(A) mRNA throughout the cell cycle, with an increase in G2/M (Fig. 3a, b), as reported previously<sup>38,39</sup>. As the DTB-synchronised cells progressed through S-phase, the amount of H2A.X poly(A) mRNA increased (see change from 3 hr to 6 hr time points in Fig. 3a, b), suggesting that a fraction of H2A.X poly(A) mRNA is

synthesised during the S-phase. Similarly, in RPE-1 cells, H2A.X poly(A) mRNA was expressed at very low levels in G0 and increased as cells progressed to G1 and into S-phase (Fig. 3c). In contrast, H2A.X SL mRNA paralleled S-phase-specific H4 SL mRNA expression in all three cell lines increasing at the onset of S-phase and rapidly decreasing with S-phase completion. The half-life of the H2A.X SL mRNA was previously found to be comparable to bulk histone mRNA (35–40 min)<sup>24,40</sup>, and the H2A.X poly(A) a 6-fold longer half-life of about 4 hr<sup>41</sup>. Notably, S-phase HCT-116 cells expressed higher H2A.X SL mRNA levels as compared to HeLa and RPE-1 cells. This is consistent with increased H2A.X SL mRNA synthesis during the S-phase in HCT-116 cells (compare H2A.X poly(A) versus SL mRNA in orange boxes in Fig. 3a–c). Furthermore, this increase was specific for H2A.X SL mRNA as H4 SL mRNA levels were comparable between the three cell lines (Fig. 2a). This excludes the possibility that increased H2A.X SL mRNA levels as observed in asynchronous cell populations are simply due to differential cell cycle phase distributions.

*H2AFX* is located outside of the histone gene clusters and its promoter is not bound by NPAT at significant levels<sup>42</sup> (Supplementary Fig. 2b). Thus, it is likely that *H2A.X* mRNA expression (including *H2A.X* SL mRNA) is regulated independently of RD histone genes. Interestingly, we observed 1.5-fold higher U7 snRNA levels in HCT-116 than HeLa or RPE-1 cells (Supplementary Fig. 3a). Even though U7 snRNP is concentrated in the HLB, cells with increased U7 snRNA levels may potentially have more U7 snRNP in the nucleoplasm and so allow for more efficient processing at the *H2A.X* SL-HDE site. This may be consistent with higher levels of *H2A.X* SL mRNA in HCT-116 cells. To test this hypothesis, we overexpressed the U7 snRNP in HeLa cells using a novel strategy developed by Sarah Tisdale and Livio Pellizzoni (personal communication). They found that coexpression of the U7 snRNP-specific proteins LSM10 and LSM11 increases U7 snRNP biogenesis and function. We generated a HeLa Flp-In T-REx cell line that overexpresses LSM10 and LSM11 in a doxycycline-inducible manner. Notably, U7 snRNA levels increased 2-fold as a result of LSM10/11 overexpression (Supplementary Fig. 3b). Even so, we did not observe an increase in *H2A.X* SL mRNA levels (Supplementary Fig. 3c). These overexpression results imply that solely raising U7 snRNA levels is insufficient to increase *H2A.X* SL mRNA expression. Likely other factors will also contribute to the variable pattern of *H2A.X* mRNA alternative isoforms as seen in the different cell lines.

**SL and poly(A) mRNAs differ in *H2A.X* chromatin incorporation and DDR.** We wished to test whether the *H2A.X* SL and poly(A) mRNA isoforms play different roles in the deposition of *H2A.X* onto chromatin and whether this affected DDR. Chromatin was therefore purified from HeLa and HCT-116 cell nuclei (Supplementary Fig. 4a) and the relative amount of *H2A.X* in this fraction in different cells was compared to core H4 levels by western blotting. As shown in Fig. 4a, asynchronously growing HCT-116 cells have 1.5-fold more *H2A.X* in chromatin compared to HeLa cells. This indicates that the higher levels of *H2A.X* SL mRNA in HCT-116 cells allow for increased *H2A.X* deposition onto chromatin during DNA replication in S-phase.

It has been shown that DNA damage induction leads to de novo *H2A.X* deposition into chromatin<sup>43</sup>. We therefore tested if the higher basal levels of *H2A.X* seen in HCT-116 as compared to HeLa cell chromatin results in differences in *H2A.X* deposition following DNA damage. HeLa and HCT-116 cells were treated with the topoisomerase II inhibitor etoposide and levels of *H2A.X* in chromatin were assessed by western blot every 30 min for 2 hr. Notably, these increased in HeLa cells (up to 3-fold) but were unchanged in HCT-116 cells (Fig. 4b). This DNA damage effect was even more dramatic for  $\gamma$ *H2A.X* with levels increasing up to 10-fold at later time points with HeLa but not with HCT-116 cells (Fig. 4c). The difference between these two cell lines in chromatin incorporation of *H2A.X* following DNA damage by etoposide treatment was mirrored by RPE-1 and Jurkat cells (Supplementary Fig. 4b–e). Thus, RPE-1 cells, which like HeLa cells, express higher levels of poly(A) than SL *H2A.X* mRNA showed a clear increase in *H2A.X* chromatin incorporation following etoposide treatment. In contrast, Jurkat cells showed only a small increase in *H2A.X* incorporation into chromatin following etoposide-induced DNA damage. However, Jurkat cells did show a significant increase in  $\gamma$ *H2A.X*, reflecting modification of existing chromatin bound *H2A.X* protein in response to DNA damage. This is consistent with the high levels of *H2A.X* SL mRNA expressed in these cells. These experiments to measure *H2A.X* chromatin incorporation following DNA damage were

reproducible between three biological repeats for all four cell types.


We also extended these data on DNA damage-induced *H2A.X* chromatin association to a different DNA damaging agent. Notably, irradiation of HeLa or HCT-116 cells with UV light displayed the same differential effects on *H2A.X* protein levels seen for etoposide treatment (Fig. 4d, e). Thus, HeLa cells showed de novo incorporation of *H2A.X* into chromatin while HCT-116 cells did not, but responded by modifying the chromatin bound *H2A.X* already present.

Taken together, these results show that cells expressing higher amounts of *H2A.X* SL mRNA such as HCT-116 and Jurkat, incorporate more *H2A.X* histone into the chromatin during DNA replication. These *H2A.X* levels are sufficient to signal DDR. In contrast, cells that express lower amounts of *H2A.X* SL mRNA, such as HeLa and RPE-1, incorporate less *H2A.X* into the chromatin during S-phase. Consequently, for efficient DDR, this lower basal *H2A.X* level must be compensated for by de novo *H2A.X* synthesis from *H2A.X* poly(A) mRNA and its incorporation into chromatin throughout the cell cycle.

***H2A.X* poly(A) mRNA is required for cell cycle progression and genome stability.** To dissect the function of the *H2A.X* poly(A) mRNA, we carried out selective depletion of this mRNA isoform by use of either a single siRNA (siRNA) or a pool of four different siRNAs (siRNAP) targeting the extended 3'-UTR (Fig. 5a). In HeLa cells, *H2A.X* poly(A) mRNA depletion was achieved following 48–72 hr of siRNA treatment and led to a substantial decrease in *H2A.X* protein levels (Fig. 5b). Surprisingly, both *H2A.X* SL and H4 SL mRNA decreased upon *H2A.X* poly(A) mRNA depletion. As histone SL mRNA is S-phase-specific, this suggested there was a reduction in the number of S-phase cells when *H2A.X* poly(A) mRNA was depleted. Flow cytometry analysis confirmed that the percentage of S-phase cells decreased by one third in cells treated with siRNAs (Fig. 5b). The number of cells in G1 was increased, suggesting a failure or delay in S-phase entry.


Similar results to HeLa were obtained with RPE-1 cells. We depleted the *H2A.X* poly(A) mRNA (Fig. 5c), synchronised the cells in G0 by contact inhibition and assessed the number of cells entering S-phase after release from the block (Fig. 5d). While indeed only half as many of the cells were able to enter S-phase when the *H2A.X* poly(A) mRNA was depleted (Fig. 5d), the cells that entered S-phase did not show an apparent DNA replication defect, as assessed by EdU incorporation followed by flow cytometry (Supplementary Fig. 5). This result is consistent with failure to initiate S-phase. To test if accumulated DNA damage might be responsible for this cell cycle defect in RPE-1 cells, pulsed-field gel electrophoresis (PFGE) was performed. As shown in Fig. 5e, cells depleted of the *H2A.X* poly(A) mRNA showed increased levels of fragmented DNA compared to the siLuc control in both G0 (0 hr) and G1 (8 hr) (green arrows in Fig. 5e). This effect was increased when the cells were treated with etoposide (red arrow in Fig. 5e). Overall, the above data demonstrate that the *H2A.X* poly(A) mRNA is important for cell cycle progression and genome stability in cells expressing higher amounts of *H2A.X* poly(A) mRNA, such as HeLa and RPE-1.

**$\gamma$ *H2A.X* signalling is impaired in HeLa cells depleted of the *H2A.X* poly(A) mRNA.** Since DNA damage leads to the phosphorylation of *H2A.X*, forming  $\gamma$ *H2A.X*, we next tested whether depletion of *H2A.X* poly(A) mRNA affects  $\gamma$ *H2A.X* signalling. HeLa cells depleted of *H2A.X* poly(A) mRNA were treated with etoposide for 2 hr before harvesting and *H2A.X*



**Fig. 4 Analysis of H2A.X deposition in chromatin upon DNA damage induction.** **a** H2A.X levels in chromatin. Western blot of fractionated chromatin from WT HeLa and HCT-116 cells. Total H2A.X and core H4 histone were detected with specific antibodies. Densitometry of western blot (right panel). Total H2A.X protein levels in HCT-116 cells are represented relative to HeLa cells and normalised to H4 histone. Mean  $\pm$  SD presented for  $n = 3$  independent experiments. Paired Student's  $t$ -test,  $*P$ -value  $\leq 0.05$ . **b** Western blot analysis of H2A.X in isolated chromatin from HeLa and HCT-116 cells treated with etoposide as indicated. H4 was used as loading control. M: protein size marker. Mean  $\pm$  SD presented for  $n = 3$  independent experiments. Unpaired Student's  $t$ -test: ns: not significant  $P$ -value  $> 0.05$ ,  $*P$ -value  $\leq 0.05$ ,  $**P$ -value  $\leq 0.01$ ,  $***P$ -value  $\leq 0.001$ ,  $****P$ -value  $\leq 0.0001$ . **c** As in **b** but for  $\gamma$ H2A.X. **d** Western blot analysis of H2A.X in isolated chromatin from HeLa and HCT-116 cells after 15 J/m<sup>2</sup> UV irradiation. H4 was used as loading control. M: protein size marker. Mean  $\pm$  SD presented for  $n = 3$  independent experiments. Unpaired Student's  $t$ -test: ns: not significant  $P$ -value  $> 0.05$ ,  $*P$ -value  $\leq 0.05$ ,  $**P$ -value  $\leq 0.01$ ,  $***P$ -value  $\leq 0.001$ . **e** As in **d** but for  $\gamma$ H2A.X.






**Fig. 5** siRNA depletion of the H2A.X poly(A) mRNA. **a** Schematic of siRNA binding sites for 3'-UTR extension of H2A.X poly(A) mRNA. siRNA: single siRNA. siRNAP: pool of four different siRNAs. **b** H2A.X mRNA northern blot of total RNA and quantification from HeLa cells treated with indicated siRNAs for 72 hr. Mean  $\pm$  SD presented for  $n = 3$  independent experiments, two-way ANOVA with Tukey's multiple comparisons test. \*\*\*\* $P$ -value  $\leq 0.0001$ , \*\*\* $P$ -value  $\leq 0.001$ . H4 SL: core H4 histone SL mRNA. 18S rRNA used as loading control (left). Total protein extract western blot and quantification. Actin and core histone H4 are controls. H2A.X indicates total H2A.X protein levels. The two 15 kDa marks indicate where the membrane was cut. Mean  $\pm$  SD presented for  $n = 3$  independent experiments, paired Student's  $t$ -test, \*\* $P$ -value  $\leq 0.01$  (top right). Percentages of cells in G1, S and G2/M analysed by flow cytometry in siRNA-treated HeLa cells. Staining for flow cytometry was performed using propidium iodide. Mean  $\pm$  SD presented for  $n = 3$  independent experiments, two-way ANOVA with Dunnett's multiple comparisons test, ns: not significant  $P$ -value  $> 0.05$ , \*\*\*\* $P$ -value  $\leq 0.0001$  (bottom right). **c** H2A.X mRNA northern blot of total RNA from RPE-1 cells depleted of H2A.X poly(A) mRNA and synchronised by contact inhibition (time following block release). H4 SL: core H4 histone SL mRNA. EEF1A1 mRNA and 18S rRNA used as loading controls. **d** Percentage of S-phase cells in RPE-1 cell population treated with either siLuc (dark grey bars) or siRNA pool (light grey bars) and synchronised by contact inhibition. X-axis represents time points in hours after release from cell cycle arrest and y-axis percentage of S-phase cells determined by EdU labelling followed by flow cytometry (Supplementary Fig. 5). Mean  $\pm$  SD presented for  $n = 4$  independent experiments. Unpaired Student's  $t$ -test ns: not significant  $P$ -value  $> 0.05$ , \*\* $P$ -value  $\leq 0.01$ , \*\*\* $P$ -value  $\leq 0.001$ . **e** H2A.X mRNA northern blot of total RNA from RPE-1 cells treated with indicated siRNAs and arrested for 4 days and harvested at indicated time points after resuming cell cycle. 5  $\mu$ M etoposide added at 6 hr (G1) for a 2 hr period. H4 SL: core H4 histone SL mRNA. EEF1A1 mRNA and 18S rRNA used as loading controls. Same samples were analysed by PFGE. Dark blue box represents ethidium bromide-stained PFGE agarose gel. Light blue regions correspond to saturated DNA signal in gel well.

mRNA (Fig. 6a) as well as protein levels (Fig. 6b) were analysed. Notably, DNA damage induction led to an accumulation of total H2A.X protein (black arrows in Fig. 6b), which likely results from a change in H2A.X mRNA translation and/or protein stability as H2A.X poly(A) mRNA levels were unaffected by the DNA damage inducing agent (Fig. 6a). Similarly, S-phase cells depleted of the H2A.X poly(A) mRNA still express the same amount of H2A.X SL mRNA relative to H4 mRNA (Fig. 6a).

To distinguish between the  $\gamma$ H2A.X signal in S-phase and non-S-phase HeLa cells we employed EdU cell imaging coupled with immunofluorescence (IF). IF analysis was performed on HeLa cells with or without siRNA mediated depletion of H2A.X poly(A) mRNA and stained with DAPI and an antibody against  $\gamma$ H2A.X. Cells were further treated with etoposide as well as labelled with EdU to label S-phase cells (Fig. 6c). This revealed that  $\gamma$ H2A.X nuclear foci are readily detected in an etoposide dependent manner. Notably, H2A.X poly(A) mRNA depletion





**Fig. 6 Effects of H2A.X poly(A) mRNA depletion under DNA damage conditions. a** H2A.X mRNA northern blot of total RNA from HeLa cells treated with siRNA for 72 hr (left panel). H4 SL: core H4 histone SL mRNA. EEF1A1 mRNA, 28S and 18S rRNA used as loading controls. Etoposide treatment (5  $\mu$ M) was performed for 2 hr before harvesting. Tubulin was used as loading control. H2A.X: total H2A.X protein.  $\gamma$ H2A.X: H2A.X phosphorylated at Ser139. M: protein size marker. H2A.X poly(A) mRNA quantification in siLuc without and with etoposide by real-time PCR (right panel). Mean  $\pm$  SD presented for  $n = 3$  independent experiments, paired Student's  $t$ -test, ns: not significant  $P$ -value  $> 0.05$ . **b** Western blot of total protein extracts from HeLa cells as indicated. Etoposide treatment (5  $\mu$ M) was performed for 2 hr before harvesting. Black arrows: total H2A.X protein in siLuc control cells before and after etoposide treatment. **c** IF of HeLa cells with etoposide treatment (5  $\mu$ M for 2 hr before harvesting). Blue: DAPI (nuclei). Red:  $\gamma$ H2A.X. White: EdU (S-phase cells). Quantification of nuclear  $\gamma$ H2A.X signal in non-S-phase (black bars) and S-phase cells (grey bars) (bottom). Mean  $\pm$  SD presented for  $n = 3$  independent experiments, two-way ANOVA with Tukey's multiple comparisons test. \*\*\*\* $P$ -value  $\leq 0.0001$  (left). **d-f** As in **a-c**, respectively, but for HCT-116 cells. The red asterisk indicates unequal loading in lane 1 of **d**.

led to a significant general decrease in  $\gamma$ H2A.X IF signal in both non-S-phase and S-phase cells (Fig. 6c). This effect was rescued by stable expression of an siRNA-resistant wild-type (WT) *H2AFX* gene (siRNA binding site deleted) but not by a poly(A) site deletion mutant (Supplementary Fig. 6a–d). This latter experiment demonstrates that decreased  $\gamma$ H2A.X signalling is specifically caused by lack of H2A.X poly(A) mRNA and not through indirect effects of perturbing H2A.X expression. We also confirmed that HeLa cells lacking the H2A.X poly(A) mRNA are

deficient in H2A.X protein incorporation into chromatin upon DNA damage induction, supporting that it is de novo H2A.X synthesised from the H2A.X poly(A) mRNA that is incorporated into the damaged chromatin (Supplementary Fig. 6e).

In contrast to HeLa, in HCT-116 cells neither depletion of H2A.X poly(A) mRNA nor induction of DNA damage with etoposide affected total H2A.X protein levels (Fig. 6d, e; see black arrows). Similarly, IF analysis of  $\gamma$ H2A.X in HCT-116 cells revealed no significant change in signal following H2A.X poly(A)

mRNA depletion (Fig. 6f). Taken together, we demonstrate that HeLa cells expressing low levels of H2A.X SL mRNA rely on the poly(A) mRNA to provide sufficient H2A.X for incorporation into chromatin and efficient  $\gamma$ H2A.X signalling. In contrast, continuously cycling cells that express higher levels of the H2A.X SL mRNA, such as HCT-116, are unaffected by the loss of the H2A.X poly(A) mRNA.

**Effect of selective H2A.X SL mRNA loss in HeLa and HCT-116 cells.** We next performed parallel experiments to study the function of H2A.X SL mRNA by its selective removal. Since the sequence of the H2A.X SL mRNA is shared with its extended polyadenylated counterpart, H2A.X SL mRNA does not contain any unique sequences that can be specifically targeted by RNAi. However, the 3'-end processing of H2A.X SL mRNA can be prevented by deletion of its HDE which is known to abolish U7-dependent processing of histone mRNA in mammalian cells<sup>44</sup>. Therefore, we targeted the *H2AFX* HDE for deletion by CRISPR-Cas9 technology in both HeLa and HCT-116 cells (Fig. 7a). A homozygous clone was obtained for each cell line (referred to as HeLa  $\Delta$ HDE and HCT-116  $\Delta$ HDE). The homozygous HeLa  $\Delta$ HDE clone also contained a 90 bp deletion downstream of the HDE deletion (Supplementary Fig. 7a). This deleted region does not contain any known sequence elements involved in the regulation of the H2A.X poly(A) mRNA and so was employed in further analysis. The SL structure is intact in both HeLa and HCT-116  $\Delta$ HDE clones so that the H2A.X poly(A) mRNA expressed in these cell lines still contains the SL, like the normal H2A.X poly(A) mRNA, which can still bind SLBP, and hence potentially stimulate translation<sup>10</sup>.

The HDE deletion completely abolished processing at the *H2AFX* U7-dependent processing site in both cell types (Fig. 7b). Consequently, the HDE deletion has a more severe effect on total levels of H2A.X mRNA in HCT-116 cells as H2A.X SL mRNA is the dominant isoform in this cell type. Interestingly, H2A.X poly(A) mRNA levels did not significantly increase in  $\Delta$ HDE cells compared to WT cells (Fig. 7b and Supplementary Fig. 7b). This was surprising as we anticipated that HDE deletion would increase the level of read-through transcription up to the PAS, particularly in the HCT-116 cells, which produce large amounts of H2A.X SL mRNA. This argues against a simple competitive effect between these two adjacent mRNA 3'-end processing machineries. Furthermore, similarly to depletion of the H2A.X poly(A) mRNA (Fig. 5b-d), HDE deletion showed an effect on cell cycle distribution, as both cell lines had 10–25% fewer S-phase cells compared to the WT (Supplementary Fig. 7c).

H2A.X SL mRNA knock out resulted in decreased levels of total H2A.X protein in both cell types with, as expected, a stronger effect in HCT-116 (Fig. 7c). As observed previously (Fig. 6b), etoposide treatment led to an increase in total H2A.X protein levels in HeLa WT cells (about 5-fold) but not in HCT-116 cells (Fig. 7c).  $\gamma$ H2A.X levels were also reduced in both  $\Delta$ HDE cell lines as compared to the WT cells (Fig. 7d). As with total H2A.X, the effect was also more pronounced in HCT-116 cells as these mainly rely on H2A.X SL mRNA to generate H2A.X. To test whether the loss of the H2A.X SL mRNA has an effect on the cells outside of the S-phase, we measured  $\gamma$ H2A.X levels by IF following etoposide treatment in S-phase and non-S-phase cells (EdU labelling). Both WT and  $\Delta$ HDE HeLa and HCT-116 cells were tested. Nuclei were stained with DAPI and specific antibodies against  $\gamma$ H2A.X (Fig. 7e, f). Nuclear  $\gamma$ H2A.X signal was quantified in non-S-phase and in S-phase cells. In HeLa cells there was no significant difference in  $\gamma$ H2A.X levels between WT and  $\Delta$ HDE cells, independent of the cell cycle phase (Fig. 7e). In contrast, HCT-116  $\Delta$ HDE cells showed decreased  $\gamma$ H2A.X signal

in both S-phase and non-S-phase cells (Fig. 7f), indicating that in these cells the H2A.X made from the SL mRNA during DNA replication is required for  $\gamma$ H2A.X signalling in later stages of the cell cycle.


Taken together, differences in severity of the  $\Delta$ HDE mutation on HeLa and HCT-116 H2A.X expression correlate with the starting level of H2A.X SL mRNA. For HeLa cells that express only small levels of this mRNA isoform, little effect on H2A.X function was detectable. In contrast, HCT-116 cells that predominantly express the S-phase H2A.X SL mRNA were more severely affected, since they did not increase the expression of H2A.X poly(A) mRNA. Overall, our results establish the following mechanism for H2A.X incorporation into chromatin (Fig. 8). In cells, such as HCT-116 and Jurkat, which are able to incorporate sufficient H2A.X into the newly synthesised chromatin during DNA replication, due to higher H2A.X SL mRNA levels, do not require de novo H2A.X incorporation for an efficient DNA damage response. In contrast, cells including HeLa and RPE-1 with lower levels of H2A.X SL mRNA display lower levels of steady state chromatin H2A.X. Consequently, upon DNA damage de novo H2A.X is immediately synthesised from pre-existing H2A.X poly(A) mRNA and incorporated into the chromatin, to efficiently signal the DNA damage.

## Discussion

The H2A.X protein has been extensively studied as a marker of DNA damage repair. However, how *H2AFX* expression is regulated through its two mRNA isoforms and what role these may play in the DNA damage response remains unknown. The aim of our study was therefore to investigate the role of these two H2A.X mRNA isoforms in the DNA damage response. It was previously observed that the H2A.X poly(A)/SL mRNA ratio significantly varies between cell lines<sup>24</sup>. Here we have compared cell lines that differentially express the two H2A.X mRNA isoforms; HeLa and RPE-1 cells with predominantly H2A.X poly(A) mRNA *versus* HCT-116 and Jurkat with mainly H2A.X SL mRNA (Fig. 2).

As summarised in Fig. 8, we show that HCT-116 and Jurkat cells contain larger amounts of H2A.X protein in their chromatin, resulting in a lower dependence on the H2A.X poly(A) mRNA for an efficient DNA damage response. Increased levels of S-phase-specific H2A.X SL mRNA allow for higher H2A.X deposition on chromatin during DNA replication. This results in a larger H2A.X/H2A protein ratio in chromatin, which is sufficient for efficient  $\gamma$ H2A.X signalling by phosphorylation of the chromatin H2A.X, both inside and outside of the S-phase. In contrast, HeLa and RPE-1 cells have lower amounts of H2A.X protein deposited in chromatin during DNA replication. Upon DNA damage induction, these cells require de novo synthesis and chromatin deposition of H2A.X from the H2A.X poly(A) mRNA isoform. This newly incorporated H2A.X in chromatin is required for sufficient H2A.X phosphorylation to form  $\gamma$ H2A.X foci. As H2A.X poly(A) mRNA levels do not change in response to DNA damage, H2A.X protein levels must be regulated through activation of translation of the mRNA and/or an increase in protein stability. In support of the latter possibility, it has been shown that under normal conditions H2A.X protein is constantly degraded by poly-ubiquitination<sup>45</sup> and thus not incorporated into chromatin, whereas DNA damage induction leads to the stabilisation of the H2A.X protein allowing incorporation into chromatin to form  $\gamma$ H2A.X foci. As we could only detect H2A.X protein in chromatin fractions but not in cytoplasmic or nucleoplasmic fractions (Supplementary Fig. 4a) we postulate that stable de novo H2A.X is immediately deposited onto chromatin.

How cells regulate different amounts of the H2A.X SL and poly(A) mRNA remains unresolved. We therefore manipulated




**Fig. 7 Effect of H2A.X SL mRNA loss in control versus DNA damage conditions.** **a** Schematic of CRISPR HDE deletion. Two guide RNAs flanking HDE were used together with a ssDNA oligonucleotide template for homologous recombination. **b** H2A.X mRNA northern blot of total RNA from asynchronous WT (WT) and  $\Delta$ HDE HeLa and HCT-116 cells. H4 SL: core H4 histone SL mRNA. EEF1A1 mRNA and 18S rRNA used as loading controls. **c, d** Western blots showing total H2A.X (**c**) and  $\gamma$ H2A.X (**d**) protein levels in WT and  $\Delta$ HDE HeLa and HCT-116 cells, with or without etoposide treatment. Tubulin: loading control. M: protein size marker. Blue (HeLa) and red (HCT-116) dotted lines highlight bands used for quantification, shown in graphs below. Quantifications represent total or  $\gamma$ H2A.X levels normalised to tubulin and relative to the WT. Mean  $\pm$  SD presented for  $n = 3$  independent experiments. Paired Student's  $t$ -test, ns: not significant  $P$ -value  $> 0.05$ ,  $*P$ -value  $\leq 0.05$ ,  $**P$ -value  $\leq 0.01$ ,  $***P$ -value  $\leq 0.001$ . **e** IF images of WT and  $\Delta$ HDE HeLa cells treated with etoposide, labelled with EdU (white). Quantification of nuclear  $\gamma$ H2A.X signal in etoposide-treated HeLa cells, comparing the  $\gamma$ H2A.X intensity between WT and  $\Delta$ HDE cells in non-S-phase or S-phase cells. 10 images of each sample were analysed for a total of three independent experiments. Mean  $\pm$  SD presented for  $n = 3$  independent experiments. Two-way ANOVA with Sidak's multiple comparisons test. ns: not significant  $P$ -value  $> 0.05$ ,  $*P$ -value  $\leq 0.05$ ,  $**P$ -value  $\leq 0.01$ . **f** Same as in **e** but for HCT-116 cells.

HCT-116 cells that normally express large amounts of SL RNA in S-phase, to prevent processing at the SL by deleting the HDE and so abolish production of H2A.X SL mRNA. Surprisingly, this did not lead to increased H2A.X poly(A) mRNA levels in the S-phase (Supplementary Fig. 7b). In effect we predict that a regulatory mechanism exists in the S-phase to prevent processing at the

downstream poly(A) site even if processing at the SL-HDE site is restricted. Similarly, we were unsuccessful in increasing the amount of H2A.X SL mRNA in HeLa cells by introducing an H2A.X transgene that had the poly(A) site removed (Supplementary Fig. 6b). While this transgene did not produce any poly(A) RNA, it produced no more SL RNA than a wild-type





**Fig. 8 Model.** In S-phase HCT-116 and Jurkat cells express increased H2A.X SL mRNA compared to HeLa and RPE-1 cells, so that they synthesise and incorporate more H2A.X protein into the newly made chromatin. Following DNA damage (etoposide treatment or UV irradiation), HeLa cells employ de novo H2A.X synthesis from H2A.X poly(A) mRNA to provide sufficient H2A.X for efficient  $\gamma$ H2A.X signalling. In contrast, HCT-116 cells already contain sufficient H2A.X in chromatin to signal DNA damage, so obviating the need for de novo H2A.X synthesis.

H2A.X transgene integrated at the same site. The fact that H2A.X SL mRNA levels did not increase implies that SL mRNA 3'-end processing is an intrinsic feature of this gene in HeLa cells.

A possible explanation for the different H2A.X mRNA isoform ratios in different cell lines may relate to U7 snRNA expression levels. Thus HCT-116 cells, which express high amounts of H2A.X SL mRNA, also express increased U7 snRNA levels (Supplementary Fig. 3a). To directly investigate this possibility, we overexpressed U7 snRNA in HeLa cells by co-expressing the proteins LSM10 and LSM11, which results in a two-fold increase in U7 snRNA levels due to the higher efficiency of U7 snRNP packaging (Supplementary Fig. 3b). However, the overexpression of U7 snRNP alone did not increase H2A.X SL mRNA levels in HeLa cells (Supplementary Fig. 3c). This does not exclude the possibility that U7 snRNA levels play a role in the regulation of H2A.X mRNA isoform ratios. However, it does indicate that higher U7 snRNA levels alone are insufficient. It is likely that other factors that bind the H2A.X pre-mRNA and/or transcription factors binding to the H2A.X promoter play a role in regulating H2A.X mRNA ratios. Overall it appears that the levels of H2A.X SL mRNA expression are maintained in cells by multiple mechanisms. In effect these levels are “hardwired” features of particular cell types.

It is apparent that different cell types have evolved distinct approaches to provide sufficient H2A.X to satisfy the needs of the DNA damage response. Rapidly dividing cells likely produce sufficient H2A.X from the S-phase-specific SL mRNA. In contrast, other cell types have elected to employ the more widely expressed poly(A) mRNA to achieve a full DNA damage response.

## Methods

**Cell culture and transfections.** RPE-1 cells were kindly provided by Jean Cook (University of North Carolina at Chapel Hill), parental HeLa Flp-In T-REx cells by

Matthias Gromeier (Duke University), HCT-116 cells by the Marzluff lab and Jurkat J76 cells by Oreste Acuto (University of Oxford).

HeLa and RPE-1 cells were maintained in high glucose Dulbecco's Modified Eagle's Medium (DMEM) and HCT-116 cells in McCoy's 5a Medium, both supplemented with 10% foetal bovine serum (FBS), 100 Units/mL penicillin and 100  $\mu$ g/mL streptomycin. Jurkat J76 cells were grown in RPMI-1640 supplemented with 10% FBS.

The human iPSC lines used have been described previously (SFC840-03-03 PMID:26905200, SFC841-03-01 PMID:27097283; and SFC856-03-04 PMID:28827786), and are available through <https://ebisc.org/>. They were derived from healthy donors recruited through StemBANCC/Oxford Parkinson's Disease Center: participants were recruited to this study having given signed informed consent, which included derivation of hiPSC lines from skin biopsies (Ethics Committee: National Health Service, Health Research Authority, NRES Committee South Central, Berkshire, UK [REC 10/H0505/71]). They were cultured at the James Martin Stem Cell Facility, University of Oxford, in feeder-free culture on geltrex in E8 medium (both Thermo Fisher).

HeLa and HCT-116 cells were transfected with siRNAs using Lipofectamine RNAiMAX (Invitrogen, #13778-150) and RPE-1 cells using Dharmafect 1 Transfection Reagent (Dharmacon, #T-2001-01), according to manufacturer instructions. siRNA sequences are listed in Supplementary Table 2. Plasmids were transfected using X-tremeGENE 9 (Sigma, # 6365787001) according to manufacturer instructions. To induce DNA damage, cells were treated with 5  $\mu$ M etoposide (Sigma, # E1383) for 2 hr.

**Cell cycle synchronisation.** Nocodazole and aphidicolin blocks were performed as described<sup>46</sup>. To synchronise HeLa cells by double thymidine block (DTB), 2 mM thymidine (Sigma, #T1895) was added and incubated for 19 hr. Cells were released from the first thymidine block by washing twice with PBS followed by the addition of fresh culture media. After 9 hr, 2 mM thymidine was added and incubated for 18 hr. After the release from the second block time points were collected. For DTB synchronisations of HCT-116 cells, 2 mM thymidine was added for 12 hr, then released and regrown for 9 hr, followed by a second block of 12 hr.

RPE-1 cells were synchronised by contact inhibition as described<sup>37</sup>. Cells were seeded to be subconfluent 24 hr later. For RNAi experiments, the cells were transfected at the subconfluent state. The day after the transfection, the cells were 100% confluent and then incubated for a total of 4 days. During this time the cells undergo contact inhibition entering G0 arrest. The cells were then split 1/10 into a new cell culture and harvested at different time points.

**Total RNA and library preparation for RNA sequencing.** Total RNA was extracted using Tri-Reagent (Sigma, #T9424) according to manufacturer instructions. Prior to library preparation, ribosomal RNA (rRNA) was depleted using the Ribo-Zero Magnetic Kit (Human/Mouse/Rat) from Illumina (#MRZH116). 500 ng ribo-depleted RNA was employed for library preparation with the NEBNext Ultra Directional RNA Library Prep Kit (Illumina, #E7420S). Libraries were analysed on a bioanalyser (Agilent 2100 Bioanalyzer system) using the Agilent High Sensitivity DNA Kit (Agilent, #5067-4626). 50 bp paired-end sequencing was performed by the Wellcome Trust Centre for Human Genetics (University of Oxford, UK).

**RNA-sequencing data processing.** Adaptors from the RNA-sequencing reads were trimmed using Cutadapt 1.8.3 and reads were mapped using Tophat 2.0.13 (with parameters -g 1 -r 3000 -no-coverage-search) to the GRCh38/hg38 reference genome. Only correctly paired and properly mapped reads were selected using SAMtools 0.1.19. The data were visualised using Bedtools 2.23.0 and scaled to the size of each library (genomeCoverageBed). The UCSC genome browser was employed to visualise the data. Note that although sequencing reads were normalised to library size, RNA level differences are only qualitative in nature, due to the various fractionation steps.

Coordinates of all annotated histone transcripts were extracted from GRCh38 Gencode v27 (Ensembl 90). Stem-loop locations were identified for any transcript (also multiple ones per gene) in regions from CDS start to (CDS end + 600 bp) by finding the following sequences: GGCTCTTTTCAGAGCC, GGCCCTTTTCAGAGCC, GGTCTTTTCAGAGCC, GGTCAAAAGAGAGCT, GGCCCTTTTCAGAGCC, CGGCTCTTTTCAGAGCC, GGCCCTTTTCAGAGCC, GGCTCTTTTCAGAGCC, GGCTCTTTTCAGAGCC, GGCTCTTTTCAGAGCC, GGCTCTTTTCAGAGCC, GGCTCTTTTCAGAGCC. All these sequences were located downstream of the CDS end. Histone genes with multiple isoforms (including spliced) were checked for evidence from the sequencing data, that the stem-loop of the longer/spliced isoform was used. If UTRs were annotated in Gencode, then regions from the CDS end to the UTR end + 2 kb (in transcriptional direction) were scanned for PAS signals (AATAAA > ATATAA > ATGAAA > TATAAA), otherwise the scan was performed for CDS end to CDS end + 2 kb. These PAS were used as indicative to check histone genes manually for usage of the PAS based on abrupt signal loss in poly(A)+ sequencing data. If the signal loss was not in the CDS end to CDS end + 2 kb region, but further downstream, that region was checked for a possible PAS.

**Fractionation of nuclear and cytoplasmic RNA or protein.** Cells were resuspended in HLB+N buffer (10 mM Tris-HCl pH 7.5, 10 mM NaCl, 2.5 mM MgCl<sub>2</sub> and 0.5% NP-40), incubated on ice for 3–10 min and pelleted at 300 × g for 3 min at 4°C. Cytoplasmic lysates were transferred to a new tube and either Tri-Reagent (Sigma, #T9424) was added for RNA isolation or the lysate was directly employed for protein quantification. The nuclear pellet was resuspended once more in HLB+N buffer and carefully overlaid on 500 µL HLB+NS buffer (HLB + N buffer with 10% sucrose). After pelleting the nuclei at 300 × g for 10 min at 4°C, the SN was removed and the nuclear pellet was lysed either in Tri-Reagent for RNA extraction or in RIPA buffer (made from 10x RIPA: 0.5 M Tris-HCl pH 7.4, 1.5 M NaCl, 2.5% sodium deoxycholate, 10% NP-40, 10 mM EDTA) for protein extraction.

**Chromatin fractionation protocol.** Cells were fractionated in cytoplasmic and nuclear fractions as described above. The nuclear pellet was resuspended in NUN1 buffer (20 mM Tris-HCl pH7.9, 75 mM NaCl, 0.5 mM EDTA pH 8.0, 50% Glycerol). Then NUN2 buffer (20 mM HEPES pH 7.6, 7.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA pH 8.0, 0.3 M NaCl, 1 M Urea, 1% NP-40) was added, followed by a 15 min incubation on ice and vortexing every 3–4 min. Chromatin was pelleted at max. speed for 2 min at 4°C. The supernatant was kept as nucleoplasmic fraction. The pellet was washed with PBS and resuspended in PBS supplemented with benzonase (2 µL per 100 µL of PBS, Sigma, # E1014), digested at 37°C for 15 min, then 4x protein loading dye (400 mM Tris-HCl pH 6.8, 10% SDS w/v, 40% Glycerol, 4 mM EDTA, 400 mM DTT and 0.1% bromophenol blue) was added to a final concentration of 1x and the lysate was incubated at 95°C for 15 min. The resulting chromatin lysate was diluted 1/5 with 1x protein loading dye and 5–10 µL were used for western blot.

**Reverse transcription and PCR.** Complementary DNA (cDNA) was made using random hexamers (Life Technologies, #48190011) and SuperScript IV Reverse Transcriptase (Life Technologies, #18090050), according to manufacturer instructions. PCR was performed with Phusion polymerase (NEB, #M0530S) and 10% 5 M Betaine (Sigma, #61962). Real-time PCR was performed with SensiMix (Bioline, #QT650-05) according to manufacturer instructions.

**Northern blot.** For H2A.X mRNA detection, RNA was separated on 1% agarose containing 5.5% v/v formaldehyde 36.5–38% in MOPS and transferred by capillarity in 10x SSC (1.5 M NaCl and 150 mM tri-sodium citrate). For U7 snRNA northern blots, RNA was separated on 8% polyacrylamide gels (60% v/v 1 × TBE containing 7 M Urea, 40% v/v 19:1 acrylamide:bisacrylamide 20%, 0.1% ammonium persulfate, 0.01% TEMED) in TBE followed by semi-dry transfer. HIST1H4A and EEFlA1 mRNA was detected with dsDNA probes, generated by PCR (primers listed in Supplementary Table 2), radioactively labelled with <sup>32</sup>P-α-dCTP (PerkinElmer, #NEG51250UC) using the Prime-IT II Random Primer Labeling Kit (Agilent, #300385), as described by the manufacturer's instructions. To detect the two H2A.X mRNA forms, a ssDNA probe was designed and ordered as custom DNA oligo with Integrated DNA Technologies (IDT) (Supplementary Table 2). This probe was end-labelled with <sup>32</sup>P-γ-ATP (PerkinElmer, #NEG5022250UC) using T4 polynucleotide kinase (NEB, #M0236S). The labelled probes (dsDNA and ssDNA) were purified using Illustra Microspin G-25 columns (GE Healthcare Life Sciences, #27-5325-01), as described by the manufacturer's instructions, and denatured at 85°C for 3 min prior addition to the tube containing the membrane and the hybridisation buffer (Sigma, #H7033). Probe hybridisation was performed for 16 hr at 65°C, rotating in a hybridisation oven.

The probes for U6 and U7 snRNA were generated by *in vitro* transcription using the MAXIScript SP6/T7 Transcription Kit (Thermo Fisher Scientific, #AM1320) and <sup>32</sup>P-α-CTP (PerkinElmer, #NEG508H250UC). The U6 and U7 snRNA sequences followed by the bacteriophage SP6 promoter sequence were cloned downstream of the T7 promoter of the pCI vector (Promega, #E1731). PCR products using T7 and SP6 forward primers were used as template for *in vitro* transcription. The antisense snRNA sequences generated with SP6 RNA polymerase were used as probes for northern blotting.

**Western blot for histone protein detection.** To detect total histone protein levels by western blot, the cell pellet was directly lysed in 4x SDS loading dye (400 mM Tris-HCl pH 6.8, 10% SDS w/v, 40% Glycerol, 4 mM EDTA, 400 mM DTT and 0.1% bromophenol blue) and incubated at 95°C for 15 min. The samples were diluted to 1x SDS loading dye and separated on 12% Bis-Tris Protein Gels (Life Technologies, #NP0342BOX) with NuPAGE MES SDS Running Buffer (Life Technologies, #NP0002). Antibodies are listed in Supplementary Table 3. All western blots shown in figures are representative of at least 3 independent experiments. Quantification by densitometry was performed using Image Studio Lite software.

#### Immunofluorescence (IF)

**Staining.** EdU labelling was performed using the Click-iT EdU Alexa Fluor 647 Imaging Kit (Thermo Fisher Scientific, #C10340), according to manufacturer's instructions. The primary antibody (γH2A.X, Milipore, #05-636) diluted 1:200 in complete tissue culture media was incubated for 2 hr at room temperature. After 3x

washes with PBS 0.01% Tween-20, the secondary antibody (Alexa Fluor 594, Life Technologies, #A11032) diluted 1:1000 in complete media was applied and incubated for 1 hr at room temperature. Following 3x more washes with PBS 0.01% Tween-20, 1:1000 DAPI staining solution was applied (Thermo Fisher Scientific, #62248). Finally, the cover slips were washed twice with water and mounted on a slide using ProLong Gold Antifade Reagent (Thermo Fisher Scientific, #P36930).

**Image acquisition.** IF imaging was performed with an Olympus FV1200 confocal laser scanning microscope. The system was equipped with a 60x/1.42-NA lens, standard photomultiplier (PMT) detectors, 655–755 nm filter (BA655-755), SDM640 and SDM490 dichroic mirrors and 405 nm, 559 nm and 635 nm lasers. Settings were adjusted to the sample with the brightest signal. All the samples from the same experiment were imaged with these same settings to be able to compare intensities between samples. Of each slide, z-stacks of 10 different fields were imaged.

**Image analysis.** The microscopy images were processed in the Image J software (version 2.0.0).

**Flow cytometry.** Propidium iodide staining<sup>46</sup> and EdU labelling followed by staining with Alexa647-azide and DAPI<sup>37</sup> were performed as described. Samples stained with propidium iodide were analysed with the BD FACS Calibur with the 488 nm laser using a 585/42 band pass filter. Samples labelled with EdU (Alexa 647) and stained with DAPI were analysed with BD LSRFortessa X-20. DAPI was detected with the 405 nm laser, a 450/50 band pass filter and a 420 nm long pass filter. Alexa 647 was detected using a 640 nm laser, a 670/30 band pass filter and a 665 nm long pass filter.

**CRISPR-Cas9 gene editing.** The CRISPR-Cas9 guide RNA (gRNA) as well as the template for homologous recombination were designed by Joey Riepsaame (University of Oxford). Target specificity of the gRNA was analysed using the CCTop online Tool (<https://crispr.cos.uni-heidelberg.de>). Two gRNAs were designed to cut around the H2AFX HDE (Supplementary Table 2). The symmetric single-stranded donor oligonucleotide (ssODN) employed as template for homologous recombination was designed in the antisense direction of the gene, with a 26 bp left homology arm and a 29 bp right homology arm and deleting nucleotides 574–598 of the H2AFX gene (counting from the first nucleotide of the 5' UTR) (Supplementary Table 2). An EcoRI restriction site was inserted between the homology arms, to facilitate the screening for positive clones.

The gRNAs were *in vitro*-transcribed as described<sup>47</sup> and assembled with recombinant Cas9 protein. For RNP formation, 1 µg of each gRNA was added to 5 µg (HiFi) Cas9 protein (IDT, #1081060) in a total volume of 20 µL IDT Duplex Buffer (IDT, #11-05-01-12), mixed by pipetting up and down for 5 times and incubated at 37°C for 5 min. Resulting RNPs were transfected into the cells together with 100 pmol of the template for homologous recombination by electroporation using the NEON Transfection System (Thermo Fisher Scientific, #MPK5000), as described below.

Cells were seeded in antibiotic-free media 24 hr before transfection. 2 hr before harvesting for transfection, cells were treated with non-homologous end joining (NHEJ) inhibitor SCR-7 (Sigma, #SML1546). Cells were washed twice with PBS and nucleofected with the pre-assembled RNPs and the ssODN (described above) in a total volume of 10 µL “buffer R” (Invitrogen, #MPK1096). For HeLa cells 1005 V, 35 ms and 2 pulses were used and for HCT-116 1530 V, 20 ms and 1 pulse. After transfection, cells were immediately transferred to a 24-well plate containing 0.5 mL antibiotics-free media supplemented with 1 µM SCR-7. The day after transfection, media was changed to media with antibiotics, without SCR-7. After 48 hr, cells were split 1/10 into a new 24-well plate and remaining cells were employed to seed 1 cell per well in a 96-well plate by fluorescence-activated cell sorting (FACS) using the BD FACSAria III, each well containing 50 µL complete media. For cell sorting, DAPI was added to avoid dead cells. Cells remaining after FACS sorting were employed for genomic DNA extraction followed by bulk PCR to assess the proportion of deletion mutants *versus* WT cells. PCR screening was performed with 5'-CGGGCGTCTGTTCTAGTGT-3' as forward primer and 5'-ACGGAGGTCCCGAAGAG-3' as reverse primer, resulting in a PCR product of 792 bp in the WT and 773 bp in the deletion mutant. To distinguish the two, the PCR product was cut with EcoRI, showing two fragments (557 bp and 216 bp) only in the EcoRI-containing deletion mutants.

#### Generation of HeLa Flp-In T-Rex stable cell lines

**H2A.X constructs.** For stable integration of H2AFX gene constructs into HeLa-FlpIn cell line, the pcDNA5-FRT-TO-eGFP-Linker plasmid, kindly provided by the Castello laboratory (Oxford University), was employed as backbone. The region containing the CMV promoter up to after the bGH (bovine growth hormone) poly(A) site was excised using MluI and SphI restriction enzymes (New England Biolabs (NEB, #N0198S and #R0182S). The linearised plasmid was gel-purified using the ZymoClean Gel DNA Recovery Kit (Zymo Research, #D4007) and dephosphorylated using the FastAP Thermosensitive Alkaline Phosphatase (Thermo Fisher Scientific, #10819230). For the insert, the H2A.X gene was amplified from HeLa genomic DNA using 5'-



CTATCGacgcgtTCCAGACGCTCTCTAGGT-3' as forward primer, binding 335 base pairs (bp) upstream of the *H2AFX* 5'UTR, thus including the *H2AFX* promoter, and containing the *MluI* restriction site. As reverse primer, 5'-TTA-CATgcatgcGTTCTCCTGGTAC GTCCCTTTCT-3' was employed, binding 1807 bp downstream of the *H2AFX* 5'UTR start, including the entire *H2AFX* gene with its own poly(A) site and containing the *SphI* restriction site. The PCR was performed with Q5 polymerase (NEB, #M0491L), HeLa genomic DNA as template. The PCR product was gel-purified, digested with *MluI* and *SphI*, gel purified once more and ligated into the linearised and dephosphorylated plasmid. Ligation was performed using T4 DNA ligase (NEB, #M0202S). The ligated product was transformed into *E. coli* XL1-Blue competent cells. Positive clones were selected by colony PCR and Sanger Sequencing using primers listed in Supplementary Table 2. The resulting plasmid called pcDNA5-FRT-*H2AFX* wt was employed as a template to make *H2AFX* mutant constructs by site-directed mutagenesis.

**LSM10/11 construct.** A pcDNA3 vector containing the mouse LSM10-2A-LSM11 cassette was kindly provided by Sarah Tisdale and Livio Pellizzoni. The cassette was transferred into the pcDNA5-FRT-TO-CMV vector described above and transfected into HeLa-Flp-In T-REx cells as described below in section "Stable integration into HeLa-Flp-In T-REx cells". To induce LSM10/11 expression, cells were treated with 1 µg/mL doxycycline for 3 days.

**Site-directed mutagenesis.** Several *H2AFX* mutants were made by site-directed mutagenesis using the pcDNA5-FRT-*H2AFX* wt plasmid as initial template. Single nucleotide point mutations were made with 100% overlapping primers, whereas for larger deletions only partially overlapping primers were designed<sup>48</sup>. PCR was performed with Q5 polymerase (NEB, #M0491L). Supplementary Table 2 shows the constructs with their corresponding mutagenesis primers, the template plasmids, the PCR melting temperatures and the deleted nucleotide positions. After DpnI (NEB, #R0176S) treatment, the plasmid was transformed in XL1-Blue *E. coli* competent cells.

**Stable integration into HeLa-Flp-In T-REx cells.** For stable integration of the construct into the HeLa-Flp-In cell line 2 µg of the FRT site-containing plasmid together with 2 µg pOGG4 Flp-recombinase Expression Vector (Thermo Fisher Scientific, #V600520) were resuspended in 200 µL Opti-MEM (Gibco, #31985-062). 12 µL X-tremeGENE 9 DNA Transfection Reagent (Sigma, #6365787001) were added and the mix incubated at room temperature for 15–30 min. During this incubation period,  $3.5 \times 10^6$  HeLa-Flp-In cells were seeded in a 10 cm dish, in 10 mL antibiotics-free media and the transfection mix was applied. 24 hr after transfection, the media was changed to DMEM containing antibiotics and 400 µg/mL Hygromycin B (Invitrogen, #10687010) to select positive cells. The day after, the media was changed again and only 150 µg/mL Hygromycin B were added. After about two days, the media was changed again to eliminate dead cells and the remaining cells were grown until the appearance of colonies. Cells were then genotyped, further expanded and frozen in multiple vials.

**Pulsed-field gel electrophoresis.** Cells were harvested using trypsin and washed with PBS. Cells were counted using a NC-3000 Advanced Image Cytometer (Chemometec). Each sample was counted twice to increase accuracy.  $0.2 \times 10^6$  cells were employed to prepare agarose plugs with the CHEF Mammalian Genomic DNA Plug Kit (BioRad, #1703591), according to the manufacturer's instructions. Pulsed-field gel electrophoresis (PFGE) was performed as previously described<sup>49</sup>.

**Quantification and statistical analysis.** Quantifications were performed from at least 3 biological replicates unless indicated otherwise in figure legend. Statistical *P*-values were calculated by multiple *t*-tests or two-way Anova using Graphpad Prism software, Version 8.1.2. ns: *P*-value >0.05. \**P*-value ≤ 0.05. \*\**P*-value ≤ 0.01. \*\*\**P*-value ≤ 0.001. \*\*\*\**P*-value ≤ 0.0001. The error bars denote SD.

**Reporting summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

Genome-wide datasets are deposited at GEO under the accession number [GSE144323](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144323). All data is available from the corresponding author upon reasonable request. Source data are provided with this paper.

Received: 10 April 2020; Accepted: 4 December 2020;

Published online: 13 January 2021

## References

- Marzluff, W. F., Gongidi, P., Woods, K. R., Jin, J. & Maltais, L. J. The human and mouse replication-dependent histone genes. *Genomics* **80**, 487–498 (2002).
- Duronio, R. J. & Marzluff, W. F. Coordinating cell cycle-regulated histone gene expression through assembly and function of the histone locus body. *RNA Biol.* **14**, 726–738 (2017).
- Tatmer, D. C. et al. Concentrating pre-mRNA processing factors in the histone locus body facilitates efficient histone mRNA biogenesis. *J. Cell Biol.* **213**, 557–570 (2016).
- Ye, X., Wei, Y., Nalepa, G. & Harper, J. W. The cyclin E/Cdk2 substrate p220 (NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. *Mol. Cell. Biol.* **23**, 8586–8600 (2003).
- Zhao, J., Dynlacht, B., Imai, T., Hori, T. & Harlow, E. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. *Genes Dev.* **12**, 456–461 (1998).
- Zhao, J. et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. *Genes Dev.* **14**, 2283–2297 (2000).
- DeLisle, A. J., Graves, R. A., Marzluff, W. F. & Johnson, L. F. Regulation of histone mRNA production and stability in serum-stimulated mouse 3T6 fibroblasts. *Mol. Cell. Biol.* **3**, 1920–1929 (1983).
- Harris, M. E. et al. Regulation of histone mRNA in the unperturbed cell cycle: evidence suggesting control at two posttranscriptional steps. *Mol. Cell. Biol.* <https://doi.org/10.1128/MCB.11.5.2416> (1991).
- Kaygun, H. & Marzluff, W. F. Translation termination is involved in histone mRNA degradation when DNA replication is inhibited. *Mol. Cell. Biol.* **25**, 6879–6888 (2005).
- Sánchez, R. & Marzluff, W. F. The stem-loop binding protein is required for efficient translation of histone mRNA in vivo and in vitro. *Mol. Cell. Biol.* **22**, 7093–7104 (2002).
- Mowry, K. L. & Steitz, J. A. Identification of the human U7 snRNP as one of several factors involved in the 3' end maturation of histone premessenger RNAs. *Science* **238**, 1682–1687 (1987).
- Dominski, Z., Yang, X. & Marzluff, W. F. The polyadenylation factor CPSF-73 is involved in histone-pre-mRNA processing. *Cell* **123**, 37–48 (2005).
- Sun, Y. et al. Structure of an active human histone pre-mRNA 3'-end processing machinery. *Science* **367**, 700–703 (2020).
- Hammond, C. M., Strømme, C. B., Huang, H., Patel, D. J. & Groth, A. Histone chaperone networks shaping chromatin function. *Nat. Rev. Mol. Cell Biol.* **18**, 141–158 (2017).
- Farber, L. J., Kort, E. J., Wang, P., Chen, J. & Teh, B. T. The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA. *Mol. Carcinog.* **49**, 215–223 (2009).
- Godfrey, A. C. et al. U7 snRNA mutations in *Drosophila* block histone pre-mRNA processing and disrupt oogenesis. *RNA* **12**, 396–409 (2006).
- Gruber, J. J. et al. Ars2 promotes proper replication-dependent histone mRNA 3' end formation. *Mol. Cell* **45**, 87–98 (2012).
- Pirngruber, J. et al. CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 3'-end processing. *EMBO Rep.* **10**, 894–900 (2009).
- Sullivan, E. et al. *Drosophila* stem loop binding protein coordinates accumulation of mature histone mRNA with cell cycle progression. *Genes Dev.* **15**, 173–187 (2001).
- Lyons, S. M. et al. A subset of replication-dependent histone mRNAs are expressed as polyadenylated RNAs in terminally differentiated tissues. *Nucleic Acids Res.* **44**, 9190–9205 (2016).
- Kari, V. et al. A subset of histone H2B genes produces polyadenylated mRNAs under a variety of cellular conditions. *PLoS ONE* **8**, e63745 (2013).
- Mannironi, C., Bonner, W. M. & Hatch, C. L. H2A.X: a histone isoprotein with a conserved C-terminal sequence, is encoded by a novel mRNA with both DNA replication type and polyA 3' processing signals. *Nucleic Acids Res.* **17**, 9113–9126 (1989).
- Ivanova, V. S., Hatch, C. L. & Bonner, W. M. Characterization of the human histone H2A.X gene. Comparison of its promoter with other H2A gene promoters. *J. Biol. Chem.* **269**, 24189–24194 (1994).
- Bonner, W. M., Mannironi, C., Orr, A., Pilch, D. R. & Hatch, C. L. Histone H2A.X gene transcription is regulated differently than transcription of other replication-linked histone genes. *Mol. Cell. Biol.* **13**, 984–992 (1993).
- Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. *J. Biol. Chem.* **273**, 5858–5868 (1998).
- Hatimy, A. A., Browne, M. J. G., Flaus, A. & Sweet, S. M. M. Histone H2AX Y142 phosphorylation is a low abundance modification. *Int. J. Mass Spectrom.* **391**, 139–145 (2015).
- Burma, S., Chen, B. P., Murphy, M., Kurimasa, A. & Chen, D. J. ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks. *J. Biol. Chem.* **276**, 42462–42467 (2001).
- Stiff, T. et al. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. *Cancer Res.* **64**, 2390–2396 (2004).
- Ward, I. M. & Chen, J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. *J. Biol. Chem.* **276**, 47759–47762 (2001).

30. Rogakou, E. P., Boon, C., Redon, C. & Bonner, W. M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. *J. Cell Biol.* **146**, 905–916 (1999).
31. Sedelnikova, O. A., Rogakou, E. P., Panyutin, I. G. & Bonner, W. M. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. *Radiat. Res.* **158**, 486–492 (2002).
32. Celeste, A. et al. Genomic instability in mice lacking histone H2AX. *Science* **296**, 922–927 (2002).
33. Paull, T. T. et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. *Curr. Biol.* **10**, 886–895 (2000).
34. Celeste, A. et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. *Nat. Cell Biol.* **5**, 675–679 (2003).
35. Kruhlak, M. J. et al. Changes in chromatin structure and mobility in living cells at sites of DNA double-strand breaks. *J. Cell Biol.* **172**, 823–834 (2006).
36. Fernandez-Capetillo, O., Lee, A., Nussenzweig, M. & Nussenzweig, A. H2AX: The histone guardian of the genome. *DNA Repair (Amst.)* **3**, 959–967 (2004).
37. Matson, J. P. et al. Intrinsic checkpoint deficiency during cell cycle re-entry from quiescence. *J. Cell Biol.* **218**, 2169–2184 (2019).
38. Dankert, J. F. et al. Cyclin F-mediated degradation of SLBP limits H2A.X accumulation and apoptosis upon genotoxic stress in G2. *Mol. Cell* **64**, 507–519 (2016).
39. Dominguez, D. et al. A high-resolution transcriptome map of cell cycle reveals novel connections between periodic genes and cancer. *Cell Res* **26**, 946–962 (2016).
40. Heintz, N., Sive, H. L. & Roeder, R. G. Regulation of human histone gene expression: kinetics of accumulation and changes in the rate of synthesis and in the half-lives of individual histone mRNAs during the HeLa cell cycle. *Mol. Cell. Biol.* (1983). <https://doi.org/10.1128/mcb.3.4.539>
41. Tani, H. et al. Genome-wide determination of RNA stability reveals hundreds of short-lived noncoding transcripts in mammals. *Genome Res.* (2012). <https://doi.org/10.1101/gr.130559.111>
42. Kaya-Okur, H. S. et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. *Nat. Commun.* **10**, 1930 (2019).
43. Piquet, S. et al. The histone chaperone FACT coordinates H2A.X-dependent signaling and repair of DNA damage. *Mol. Cell* **72**, 888–901.e7 (2018).
44. Bond, U. M., Yario, T. A. & Steitz, J. A. Multiple processing-defective mutations in a mammalian histone pre-mRNA are suppressed by compensatory changes in U7 RNA both in vivo and in vitro. *Genes Dev.* **5**, 1709–1722 (1991).
45. Atsumi, Y. et al. ATM and SIRT6/SNF2H mediate transient H2AX stabilization when DSBs form by blocking HUWE1 to allow efficient gammaH2AX foci formation. *Cell Rep.* **13**, 2728–2740 (2015).
46. Romeo, V., Griesbach, E. & Schümperli, D. CstF64: cell cycle regulation and functional role in 3' end processing of replication-dependent histone mRNAs. *Mol. Cell. Biol.* **34**, 4272–4284 (2014).
47. Gagnon, J. A. et al. Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs. *PLoS ONE* **9**, e98186 (2014).
48. Liu, H. & Naismith, J. H. An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. *BMC Biotechnol.* **8**, 91 (2008).
49. Zellweger, R. et al. Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. *J. Cell Biol.* **208**, 563–579 (2015).

## Acknowledgements

These studies were supported by an ERC Advanced Grant [339270] and Wellcome Trust Investigator Award [107928 | Z | 15 | Z] to NJP as well as an NIH grant (GM29832) to WFM. We are grateful to NJP and WFM lab members as well as to Shawn Lyons for advice and discussion. We also want to thank Sally Cowley for providing iPS cell samples, Helio Duarte Roque for help with image analysis, Sarah Tisdale and Livio Pellizzoni for the LSM10/11 construct and Joey Riepsaame for assisting with CRISPR-Cas9 genome editing.

## Author contributions

EG performed all the experimental work described in this study and was advised by MS on the bioinformatic analysis of histone gene transcription. EG and NJP together designed the project and wrote the paper with invaluable input and expertise on histone gene expression from WFM.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41467-020-20520-6>.

**Correspondence** and requests for materials should be addressed to N.J.P.

**Peer review information** *Nature Communications* thanks Falong Lu and other, anonymous, reviewers for their contributions to the peer review of this work. Peer review reports are available.

**Reprints and permission information** is available at <http://www.nature.com/reprints>



**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021

**a**



### **Supplementary Fig. 1 (related to Figure 1)**

**(a)** Cell cycle synchronisation protocol.

**(b)** Flow cytometry analysis, showing propidium iodide fluorescence (x-axis) and the cell count (y-axis). Gating was performed manually and show percentage of cells in each cell cycle phase. Top panel shows cell cycle distribution of asynchronously growing HeLa cells as control, middle panel aphidicholin-synchronised S-phase-enriched HeLa cells and bottom panel nocodazole block G1-enriched HeLa cells.

**(c)** RNA fractionation steps for RNA-seq analysis. Note that nuclear RNA fraction contains nucleoplasmic (NP) as well as chromatin-bound (Chr) RNA. Fractionation efficiency was assessed by western blot with antibodies against tubulin (cytoplasmic) and spliceosomal U1A (nuclear). M: protein size marker.


**(d)** RNA-seq profiles of replication-dependent histone genes that generate exclusively poly(A)- SL mRNA. RNA-seq reads aligned to human genome, visualised with NCBI Genome Browser. Different tracks correspond to reads from the different fractions indicated on the left. Nuc: nuclear RNA fraction. Cyt: cytoplasmic RNA fraction. pA-: rRNA-depleted poly(A)- RNA fraction. pA+: poly(A)+ RNA fraction. S: S-phase-enriched cells. G1: G1-phase-enriched cells. SL: U7-dependent cleavage site. pA: polyadenylation site. Black arrow: direction of Pol II transcription. Green arrows: poly(A)- histone mRNA in G1 fractions most likely resulting from the remaining 3% of S-phase cells in the G1-enriched population (see percentages shown in Supplementary Fig. 1b).

**(e)** RNA-seq profiles of histone genes that express some poly(A)+ mRNA. Description as in (d).


**(f)** RNA-seq profiles of histone genes that express a fraction of intron-containing poly(A)+ mRNA. Description as in (d). We observed that the same histone genes that express polyadenylated mRNA in non-dividing tissues<sup>20</sup> express small amounts of polyadenylated histone mRNA in HeLa cells. Analysis of ENCODE data showed other cell lines, including human embryonic stem cells, all expressed small amounts of polyadenylated RNA from the same genes.

Supplementary Figure 2

a



b




Supplementary Fig. 2 (related to Figure 2)

**a)** Flow cytometry gating strategy. First, living cells were separated from cell debris using a FCS-A vs SSC-A density plot. From this population, single cells were selected in a FSC-H vs FSC-W density plot. Remaining doublets were eliminated by selecting the single cell population in a DAPI-A vs DAPI-W density plot. Singlets were then plotted as a DAPI-A vs cell count histogram to visualise the cell cycle profile and as a DAPI-A vs EdU-Alexa Fluor 647-A density plot to separate S-phase cells from G1- and G2/M-phase cells.

**b)** Cut&Tag profiling of the RD histone gene-specific transcription factor NPAT on the RD histone genes and H2AFX in human K562 cells<sup>42</sup>. Scale (number of reads) indicated in red. Note strong NPAT binding to the promoters of 20 RD histone genes from a portion of histone cluster 1 on chromosome 6 (top) and to the solitary HIST4H4 gene on chromosome 12 (bottom left). In contrast, there is very low NPAT signal on H2AFX on chromosome 11 (bottom right).



## Supplementary Fig. 3.




### Supplementary Fig. 3 (related to Figure 3)

**(a)** U7 and U6 snRNA northern blot of total RNA from HeLa, HCT-116 and RPE-1 cells. Total RNA on agarose gel as loading control (bottom panel). Densitometry quantification (right panel). Mean  $\pm$  SD presented for  $n=3$ . Paired Student's  $t$ -test, ns: not significant  $P$ -value  $> 0.05$ , \* $P$ -value  $\leq 0.05$ .

**(b)** U7 snRNA northern blot of total RNA from HeLa Flp-In T-REx LSM10/11 cells treated with 1  $\mu$ g/mL doxycycline for the indicated time (days). U6 snRNA was used as loading control. Shorter exposure of the same blot (right panel). Quantification by densitometry shown as fold increase following doxycycline induction.

**(c)** H2A.X mRNA northern blot of total RNA from samples shown in (b). 18S rRNA used as loading control.

# Supplementary Figure 4



**Supplementary Fig. 4 (related to Figure 4)**

**(a)** Analysis of HeLa and HCT-116 cell fractionations by western blotting: cytoplasmic (Cyt), nucleoplasmic (NP) and chromatin (Chr) fractions. Left panel shows Ponceau S staining. Right panel shows Lamin B1 (nuclear lamina), Tubulin (cytoplasmic), total H2A.X and H4 (chromatin) levels detected using specific antibodies. M: protein size marker.

**(b)** Western blot analysis of H2A.X in isolated chromatin from RPE-1 cells treated with etoposide as indicated. H4 was used as loading control. M: protein size marker. Mean  $\pm$  SD presented for n=3 independent experiments.


**(c)** As in (b) but for  $\gamma$ H2A.X. The membrane was cut at the 15 kDa mark.

**(d)** Western blot analysis of H2A.X in isolated chromatin from Jurkat cells treated with etoposide as indicated. H4 was used as loading control. M: protein size marker. Mean  $\pm$  SD presented for n=3 independent experiments.

**(e)** As in (d) but for  $\gamma$ H2A.X.

# Supplementary Figure 5


RPE-1



**Supplementary Fig. 5 (related to Figure 5d)**  
Flow cytometry of EdU-labelled RPE-1 cells depleted of H2A.X poly(A) RNA and synchronised by contact inhibition. Left and right columns represent siLuc and siRNAp transfected cells, respectively. Orange numbers indicate time in hours after cell release from G0 arrest. X-axis represents fluorescent intensity of DAPI and y-axis of Alexa 647-EdU. Percentages of cells in G1, S and G2/M were analysed using FlowJo software.

Supplementary Figure 6

HeLa Flp-In T-REx







**Supplementary Fig. 6 (related to Figure 6)**

- (a)** siRNA-resistant mRNA isoforms expressed from transgenes stably introduced into HeLa-Flp-In T-REx cells. Upper transcript: siRNA-resistant WT H2AFX gene. Bottom transcript additionally lacks a 26 bp region including the PAS. The H2AFX transgene contains a HindIII site in the ORF allowing its distinction from the endogenous gene by PCR. Such PCR on genomic DNA from these cell lines followed by HindIII digestion of the PCR amplicon showed that the ratio endogenous (uncut) versus transgene (cut) was 2:1 (data not shown). As the parental HeLa cell only has one FRT site, this showed that these HeLa cells have two endogenous H2AFX genes.
- (b)** H2A.X mRNA northern blot of total RNA from siRNA-resistant cell lines treated with indicated siRNAs for 72 hr, without or with etoposide. H4 SL: core H4 histone SL mRNA. EEF1A1 mRNA and 18S rRNA used as loading controls. Red boxes highlight samples used for IF, shown in (c) and (d).
- (c, d)** IF images of siRNA-resistant HeLa-FlpIn-H2AFX (c) and HeLa-FlpIn-H2AFX-ΔPAS (d) cells. Cells were labelled with EdU (S-phase cells, white) and stained with DAPI (nuclei, blue) and anti-γH2A.X antibody by IF (red). γH2A.X quantifications in S-phase and non-Sphase cells shown below. These experiments demonstrate that the reduced γH2A.X signal is specifically caused by the loss of H2A.X poly(A) mRNA and not due to indirect effects.
- (e)** Western blot analysis of chromatin fraction purified from HeLa cells depleted for H2A.X poly(A) mRNA by RNAi for 72h and treated with etoposide as shown. Quantitation of these data with error bars representing standard deviation between two independent experiments. In Figure 4 we show that HeLa cells incorporate H2A.X protein into chromatin upon DNA damage. Figure 6b shows that DNA damage induction leads to increased H2A.X protein levels, suggesting that it is de novo H2A.X that is incorporated into the damaged chromatin. This experiment now shows that the H2A.X poly(A) mRNA is required for this deposition confirming that newly translated H2A.X is incorporated.



Supplementary Figure 7



### **Supplementary Fig. 7 (related to Figure 7)**

**(a)** Sequenced PCR product from genomic DNA from the HeLa  $\Delta$ HDE CRISPR clone aligned to the wild-type H2A.X gene sequence using SnapGene software. A single stranded DNA oligonucleotide missing the region containing the histone downstream element (HDE) was used as template for homologous recombination. To facilitate screening for positive clones an EcoRI site (GAATTC) was instead inserted. The only PCR product obtained from the positive HeLa  $\Delta$ HDE CRISPR clone also contained a 90 bp deletion downstream. Alterations to the reference sequence are highlighted in pink and deletions indicated by dashed lines.

**(b)** H2A.X mRNA northern blot of total RNA from DTB-synchronised WT and  $\Delta$ HDE HeLa and HCT-116 cells. H4 SL: core H4 histone SL mRNA. 18S rRNA used as loading control. Time points indicate hours after release from DTB. Corresponding cell cycle phases determined by flow cytometry (data not shown) are indicated above. The deletion of the HDE abolishes the formation of the H2A.X SL mRNA because the U7 snRNA-dependent processing reaction fails to occur. As H2A.X poly(A) mRNA levels only show a mild increase in the S-phase when the HDE is deleted (specially clear in HCT-116 cells), which argues against a simple competitive effect between these two adjacent mRNA 3' end processing machineries.

**(c)** Flow cytometry of EdU-labelled cells. Graphs show DAPI fluorescent intensity on x-axis and Alexa 647-EdU fluorescent intensity on y-axis. Percentages of cells in G1, S and G2/M were determined using FlowJo software. HeLa cells show a 25% reduction in S-phase cells when the HDE is deleted (from 40% in WT to 30% in  $\Delta$ HDE) and HCT-116 a 10% reduction (from 50% in WT to 45% in  $\Delta$ HDE).

# Supplementary Table 1

Gene	Strand	Chromosome	PAS coordinates
<b>Histone genes that only express a SL mRNA (RD histone genes)</b>			
HIST1H1B	-	chr6	unused
HIST1H1E	+	chr6	in tandem gene 3'UTR?
HIST1H2AD	-	chr6	unused
HIST1H2AL	+	chr6	unused
HIST1H2BB	-	chr6	<a href="#">chr6:26041730-26041735</a> , unused?
HIST1H2BI	+	chr6	unused
HIST1H3C	+	chr6	unused
HIST1H3J	-	chr6	no PAS
HIST1H4A	+	chr6	unused?
HIST2H2AB	-	chr1	unused
HIST2H3D	-	chr1	unused
HIST3H3	-	chr1	unused
HIST1H4C	+	chr6	unused
HIST1H2BE	+	chr6	<a href="#">chr6:26184636-26184641</a> , unused?
HIST4H4	-	chr12	chr12:14767659-14767664 (?)
HIST1H2BO	+	chr6	unknown
HIST1H3A	+	chr6	<a href="#">chr6:26021434-26021439</a>
HIST1H4D	-	chr6	chr6:26186757-26186762 (?)
HIST1H1T	-	chr6	<a href="#">chr6:26106436-26106441</a>
HIST1H2AB	-	chr6	<a href="#">chr6:26032443-26032448</a>
HIST1H2AH	+	chr6	unknown
HIST1H2AJ	-	chr6	<a href="#">chr6:27813617-27813622</a>
HIST1H2AK	-	chr6	<a href="#">chr6:27836022-27836027</a>
HIST1H2BM	+	chr6	chr6:27817468-27817473
HIST1H4J	+	chr6	<a href="#">chr6:27825809-27825814</a>
HIST2H3A	+	chr1	<a href="#">chr1:149854251-149854256</a>
HIST2H3C	-	chr1	<a href="#">chr1:149839556-149839561</a>
HIST3H2BB	+	chr1	<a href="#">chr1:228460308-228460313</a>
HIST1H3F	-	chr6	<a href="#">chr6:26248584-26248589</a>
HIST2H2AC	+	chr1	possibly chr1:149888153-149888158
HIST2H2BF	-	chr1	<a href="#">chr1:149805890-149805895</a>
HIST1H3E	+	chr6	<a href="#">chr6:26227452-26227457</a>
HIST1H2BN	+	chr6	chr6:27855557-27855562 (possibly multiple)
HIST1H3B	-	chr6	<a href="#">chr6:26030082-26030087</a>
HIST1H4I	+	chr6	<a href="#">chr6:27140615-27140620 (?)</a>
<b>Histone genes expressing poly(A)+ mRNA that is exported to the cytoplasm</b>			
HIST1H1C	-	chr6	<a href="#">chr6:26055726-26055731</a>
HIST2H2AA3	-	chr1	<a href="#">chr1:149842204-149842209</a>
HIST2H2AA4	+	chr1	<a href="#">chr1:149851603-149851608</a>
HIST1H2AG	+	chr6	<a href="#">chr6:27135269-27135274</a>
HIST1H2BF	+	chr6	<a href="#">chr6:26202679-26202684</a>
HIST1H2BG	-	chr6	<a href="#">chr6:26214086-26214091</a>
HIST1H2BL	-	chr6	<a href="#">chr6:27805608-27805613</a>
HIST1H3H	+	chr6	<a href="#">chr6:27811278-27811283</a>
HIST2H2BE	-	chr1	<a href="#">chr1:149884477-149884482</a>
HIST2H4B	-	chr1	<a href="#">chr1:149860100-149860105</a>
HIST3H2A	-	chr1	chr1:228456997-228457002
HIST1H2AI	+	chr6	<a href="#">chr6:27809882-27809887</a>
HIST1H3G	-	chr6	<a href="#">chr6:26269421-26269426 (?)</a>
HIST2H4A	+	chr1	<a href="#">chr1:149834607-149834612</a>
HIST1H2AM	-	chr6	chr6:27891259-27891264 (?)
HIST1H2BH	+	chr6	<a href="#">chr6:26253689-26253694</a>
HIST1H4E	+	chr6	<a href="#">chr6:26206016-26206021</a>
HIST1H4K	-	chr6	unknown
HIST1H4B	-	chr6	unknown
<b>Histone genes expressing spliced poly(A)+ mRNA that is exported to the cytoplasm</b>			
HIST1H2BC	-	chr6	<a href="#">chr6:26113185-26113190</a>
HIST1H2AC	+	chr6	<a href="#">chr6:26138935-26138940</a>
HIST1H2BD	+	chr6	<a href="#">chr6:26171325-26171330</a>
HIST1H2AE	+	chr6	<a href="#">chr6:26218348-26218353</a>
HIST1H4H	-	chr6	chr6:26277620-26277625 / chr6:26281074-26281079
HIST1H2BJ	-	chr6	chr6:27125912-27125917 (probably further downstream)
HIST1H3D	-	chr6	<a href="#">chr6:26194219-26194224</a>
HIST1H2BK	-	chr6	chr6:27138313-27138318

# Supplementary Table 2

## Primers used for PCR products used as templates for northern blot probes

ACTB-Fw	GGATTCTATGTGGGCGACG	Designed by Silvia Ramos (University of North Carolina at Chapel Hill)
ACTB-Rev	GTAGTCAGTCAGGTCCCGGC	
EEF1A1-Fw	TGACTGTGCTGCTCCTGATTG	
EEF1A1-Rev	CCAAAGGTGGATAGTCTGAGAA	
HIST1H4A-Fw	TGGAGAACGTGATCCGTGAC	
HIST1H4A-Rev	ATCAGCAACCTTAACCGCCA	

## Primers used for real-time PCR

H2AX_pA+_Fw_EG	GGTGCTTAGCCCAGGACTTT
H2AX_pA+_Rev_EG	CCCAGCGCAGACCTATGAAT
rDNA-18S-down-fw	ATGGCCGTCTTAGTTGGTG
rDNA-18S-down-rev	CGCTGAGCCAGTCAGTGTAG

<b>H2AFX northern blot probe:</b>	GTGGTGGCATGGGGAGGCCT GGCGGCCCGCCGCGGCGCGG GCCCTCTTAGTACTCCTGGGA GGCCTGGGTGGCCTTCTTGCC GCCCCA
-----------------------------------	--

## Primers to amplify H2A.X poly(A) mRNA isoforms

H2A.X Total Fw-1	CGGGCGTCTGTTCTAGTGTT
H2A.X Total Rev-2	CGGGCCCTCTTAGTACTCCT
H2A.X July18 Fw-C	AGTGCTGGAGTACCTCACCG
H2A.X July18 Rev-C	GAAGGCCCGAACCTTACC

## Primers to PCR the H2AX gene with its own promoter from HeLa gDNA

H2AFX_MluI_Fw_2_EG	CTATCGacgcgtTTCGACGCTCTCTAGGT
H2AFX_SphI_Rev_2_EC	TTACATgcatgcTTCTCCTGGTACGTCCTTTCT

## QuikChange primers and constructs

Construct	mutagenesis primers (name)	mutagenesis primers (sequence)	plasmid used as template	Tm (°C)	Mutation
pcDNA5-FRT-TO-H2AX_HindIII	H2AX-HindIII_Quik_Fw_EG	GTCACGCCGCCAGAAGCTTGT	pcDNA5-FRT-TO-H2AX_wt	55	nt 364 G to T
	H2AX-HindIII_Quik_Rev_EG	TGAGCTC GAGCTCAACAAGCTTCTGGGCG GCGTGAC			
pcDNA5-FRT-TO-H2AX_HindIII_dsi3	H2AFX-del-siRNA3-Fw_EG	TCAACTCGGCAAGTCGGTTAATC CCTGTCTGGACTGAGCCTCCGTT GGCT	pcDNA5-FRT-TO-H2AX_HindIII	55	1430-1454
	H2AFX-del-siRNA3-Rev_EG	CCGACTTGCCGAGTTGAGTTTGC TGGAAGGGAAATGGGCGGCG			
pcDNA5-FRT-TO-H2AX_HindIII_dsi3_dP AS	H2AFX-dPAS-Fw_EG	ATGGACTAAAAATGGAGCGTTT GTTTTCATTTTGCAAGAGAGTTG TAGAATTAGTGAC	pcDNA5-FRT-TO-H2AX_HindIII_dsi3	55	1430-1454 and 1566-1592
	H2AFX-dPAS-Rev_EG	GCTCCATTTTGTCCATCTAAAA CTCCCCAATGCCTAAGGTTCTAG			

## Primers for sequencing the Flp-In plasmids

Seq Primer 1-Fw	AAGCCAGTATCTGCTCCCTG
Seq Primer 2-Fw	CGGTATTGGAGAAAAGAGCC
Seq Primer 3-Fw	CGGCAGTGCTGGAGTACC
Seq Primer 4-Fw	TGCTGCCCAAGAAGACCAG
Seq Primer 5-Fw	GTAGGGTTCGGGCCTTCC
Seq Primer 6-Fw	CAGGCCTTTCACATCAGCTC
Seq Primer 7-Fw	CTCAACTCGGCAATCCAAGC
Seq Primer 1-Rev	CTTAATGCGCCGCTACAGG

## CRISPR oligonucleotides

Guide RNA 1	taatacgactcactatagGGCGGTGG TGGCCCTTAAAgttttagagctaga aatagcaa	(protospacer sequence in capital letters)
Guide RNA 2	taatacgactcactataggCTGAGCCG CTTCAGACTGCGgttttagagctaga aatagca	
ssODN:	G*C*GGCCCGCTTGCCCCGACG TCTGAAGCGAATTCTGGTGGC CCTTAAAAGGGCCTTTG*T*G	(*denote phosphorothioate bonds)

siRNA	Company	Sequence or supplier ID
siLuc (custom siRNA)	Sigma	Sense sequence (5'-3') : GAUUAUGUCCGGUUAUGUAUU Antisense sequence (5'-3'): [phos]UACAUAAACCGACAUAAU CUU
H2A.X siRNA pool (siRNAp)	Dharmacon	L-011682-00-0005
H2A.X Single siRNA (siRNA)	Integrated DNA Technologies	Sense sequence (5'-3') : CAAUCCAAGCACCUGAUACCA GCA Antisense sequence (5'-3'): UGCUGUAUCUAGGUGCUUGG AUUGCC

## Supplementary Table 3

### Antibodies for WB

#### Primary

Actin	Sigma	Cat#A2066, RRID: AB_476693
Tubulin	Sigma	Cat#T5168, RRID: AB_477579
Total H2A.X	Bethyl	Cat#A300-082A, RRID: AB_203287
YH2A.X S139 Clone JBW301	Milipore	Cat#05-636, RRID: AB_309864
H4	abcam	Cat#ab17036, RRID: AB_1209245
U1A	abcam	Cat#ab166890
Lamin B1	abcam	Cat#ab8982, RRID: AB_1640627

#### Secondary

IRDye 800CW	Life Technologies	Cat#926-32211, RRID: AB_621843
IRDye 680RD	Life Technologies	Cat#926-68070, RRID: AB_10956588